Polymeric nanoparticles loaded with Paclitaxel for improved cancer therapy

Fabrication and characterization

Authors

  • Jaswinder Singh Research Scholar, I.K.Gujral Punjab Technical University, Jalandhar-Kapurthala Highway, Kapurthala Punjab. India 144 603.
  • Satvinder Kaur Professor, Department of Pharmaceutical Chemistry, GHG Khalsa College of Pharmacy, Gurusar Sadhar, Ludhiana -141104

Keywords:

Paclitaxel, Soluplus®, Anticancer, Surfactant, Nanoparticle

Abstract

Paclitaxel (PTX) is well known for its effectiveness in management of cancer. It is associated with solubility problem which is overcome by adding ethanol and Cremophor EL and is available commercially as Taxol. However, Cremophor EL has serious side effects, therefore it is imperative to utilize some other strategies or delivery system for improving its antitumor activity and reduce side effects. The prime objective of this present study was to prepare (Paclitaxel) loaded surface folate decorated and pegylated PLGA (PPF) nanoparticles and characterized for its particle size, polydispersity index, zeta potential, drug loading, drug entrapment efficiency and in vitro drug release. Based upon the in vitro drug release characteristics results the best formulation F4 was selected for observing its surface morphology by SEM and TEM. In vitro release kinetics study unveils that the delivery system follows Korsmeyer-Peppas model suggesting “Fiskian diffusion”.

Downloads

Download data is not yet available.

References

Aygül G, Yerlikaya F, Caban S, Vural İ, Çapan Y. Formulation and in Vitro Evaluation of Paclitaxel Loaded Nanoparticles, Hacettepe University Journal of the Faculty of Pharmacy, 2013;33(1):25-40.

Danhier F, Lecouturier N, Vroman B, Jérôme C, Marchand-Brynaert J, Feron O, et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation, Journal of controlled release : official journal of the Controlled Release Society, 2009;133(1):11-7.

Vicari L, Musumeci T, Giannone I, Adamo L, Conticello C, De Maria R, et al. Paclitaxel loading in PLGA nanospheres affected the in vitro drug cell accumulation and antiproliferative activity, BMC cancer, 2008;8:212.

Maji R, Dey NS, Satapathy BS, Mukherjee B, Mondal S. Preparation and characterization of Tamoxifen citrate loaded nanoparticles for breast cancer therapy, International journal of nanomedicine, 2014;9:3107.

Cetin M, Atila A, Kadioglu Y. Formulation and in vitro characterization of Eudragit® L100 and Eudragit® L100-PLGA nanoparticles containing diclofenac sodium, AAPS PharmSciTech, 2010;11(3):1250-6.

Averineni RK, Shavi GV, Gurram AK, Deshpande PB, Arumugam K, Maliyakkal N, et al. PLGA 50: 50 nanoparticles of paclitaxel: development, in vitro anti-tumor activity in BT-549 cells and in vivo evaluation, 2012;35(3):319-26.

Chen J, Li S, Shen Q, He H, Zhang Y. Enhanced cellular uptake of folic acid–conjugated PLGA–PEG nanoparticles loaded with vincristine sulfate in human breast cancer, Drug development industrial pharmacy, 2011;37(11):1339-46.

Dora CP, Singh SK, Kumar S, Datusalia AK, Deep A. Development and characterization of nanoparticles of glibenclamide by solvent displacement method, Acta pol pharm, 2010;67(3):283-90.

Jana U, Mohanty AK, Pal SL, Manna PK, Mohanta GP. Felodipine loaded PLGA nanoparticles: preparation, physicochemical characterization and in vivo toxicity study, Nano Convergence, 2014;1(1):31.

Cao L-B, Zeng S, Zhao W. Highly Stable PEGylated Poly(lactic-coglycolic acid) (PLGA) Nanoparticles for the Effective Delivery of Docetaxel in Prostate Cancers, Nanoscale research letters, 2016;11(305):1-9.

Ahmed S, Kaur K. Design, synthesis, and validation of an in vitro platform peptide-whole cell screening assay using MTT reagent, Journal of Taibah University for Science, 2017;11(3):487-96.

Lupu AR, Popescu T. The noncellular reduction of MTT tetrazolium salt by TiO(2) nanoparticles and its implications for cytotoxicity assays, Toxicology in vitro : an international journal published in association with BIBRA, 2013;27(5):1445-50.

Halayqa M, Domańska U. PLGA biodegradable nanoparticles containing perphenazine or chlorpromazine hydrochloride: effect of formulation and release, International journal of molecular sciences, 2014;15(12):23909-23.

Jana U, Mohanty AK, Pal SL, Manna PK, Mohanta GP. Felodipine loaded PLGA nanoparticles: preparation, physicochemical characterization and in vivo toxicity study, Nano Convergence, 2014;1(1):1-10.

Stevanović M, Radulović A, Jordović B, Uskoković D. Poly (DL-lactide-co-glycolide) nanospheres for the sustained release of folic acid, Journal of Biomedical Nanotechnology, 2008;4(3):349-58.

Surolia R, Pachauri M, Ghosh PC. Preparation and characterization of monensin loaded PLGA nanoparticles: in vitro anti-malarial activity against Plasmodium falciparum, Journal of Biomedical Nanotechnology, 2012;8(1):172-81.

Published

13-10-2022

How to Cite

Singh, J., & Kaur, S. (2022). Polymeric nanoparticles loaded with Paclitaxel for improved cancer therapy: Fabrication and characterization. International Journal of Health Sciences, 6(S9), 3551–3565. Retrieved from https://sciencescholar.us/journal/index.php/ijhs/article/view/13370

Issue

Vol. 6 No. S9 (2022)

Section

Peer Review Articles
Copyright & Licensing

Copyright (c) 2022 International journal of health sciences

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.

Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.

This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.